PACB vs PRCT Stock Comparison
PRCT currently leads PACB in this stock comparison, with AIQ scores of 49 vs 48. The clearest difference is risk resilience, while PACB has the stronger momentum profile.
What is the main difference between PACB and PRCT?
PRCT leads the current stock comparison as PROCEPT BioRobotics Corporation, with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Pacific Biosciences of California, Inc. vs PROCEPT BioRobotics Corporation
PRCT leads
PRCT leads by 1 AIQ points, primarily on Risk Resilience and Value.
Fragile: 4 of 6 evidence groups support PRCT, and its current signal state is conflicted.
Pacific Biosciences of California, Inc.
PROCEPT BioRobotics Corporation
The Algovestiq AIQ Score currently favors PRCT over PACB, 49 versus 48 as of Nov 18, 2026. PRCT's advantage is driven primarily by stronger risk resilience and value, while PACB holds the stronger momentum profile. PRCT also shows the stronger technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor PRCT today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. PRCT lead: Stable — the AIQ differential has held near 1 points over 30 sessions.
Compare Pacific Biosciences of California, Inc. and PROCEPT BioRobotics Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare PACB and PRCT against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum84 vs 60PACB +24
- Risk Resilience24 vs 45PRCT +21
- Value23 vs 38PRCT +15
- Quality32 vs 45PRCT +13
4 of 6 evidence groups favor PRCT. PRCT’s edge is concentrated in risk resilience and value; PACB keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.
Largest factor move: Value -1, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- Stochastic Oversold Bounce — bullish, momentum, short horizon
Largest factor move: Value -1, not enough on its own to move the overall score.
New signals
- Accumulation Pattern — bullish, volume, medium horizon (1.27x)
PRCT's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — PACB and PRCT both carry a full feed there.
The central trade-off
PRCT (PROCEPT BioRobotics Corporation): the stronger current systematic profile, led by risk resilience and value.
PACB (Pacific Biosciences of California, Inc.): the counter-case, on momentum — but at materially higher volatility, 114.1% against 64%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
PRCTPRCT on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PACBPACB on combined revenue and EPS growth.
Value
PRCTPRCT on the peer-relative Value factor, by 15 points.
Momentum
PACBPACB on the Momentum factor, by 24 points.
Lower downside
PRCTPRCT on Risk Resilience, by 21 points.
Analyst upside
PRCTPRCT on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | PACB | PRCT | Note |
|---|---|---|---|
| Implied upside to target | +5.2% | +19.1% | PRCT has more room |
| Target dispersion | +59.7% | 0% | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 8 | 15 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor PRCT. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 48 vs 49 |
| Fundamentals | Even | revenue growth 4% vs 4%; EPS growth 14.3% vs 2.1%; TTM ROE 61.7% vs -8.1%; gross margin 34.5% vs 64.7%; operating margin -99.6% vs -33.6% |
| Valuation | PRCT | Value 23 vs 38 |
| Technicals | PRCT | Price vs 50-day -8.7% vs 29%; vs 200-day 22.4% vs 3.9% |
| Risk Resilience | PRCT | Risk Resilience 24 vs 45 |
| Analyst expectations | PRCT | Target upside 5.2% vs 19.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PACB and PRCT and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PRCT.
How the comparison changed
120 daily snapshots · Jun 1 – Nov 18PRCT lead: Stable — the AIQ differential has held near 1 points over 30 sessions.
- Today
- PRCT +1
- 48 vs 49
- 7 sessions ago
- PACB +3
- 49 vs 46
- 30 sessions ago
- PRCT +1
- 44 vs 45
- 90 sessions ago
- PRCT +9
- 30 vs 39
The lead changed hands 4 times in this window, most recently on Oct 28 when PACB moved ahead of PRCT.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 3 bearish / 1 neutral, conflicted
Only PACB
- Golden Cross Active — bullish, trend, long horizon (25.22%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
- Stochastic Oversold Bounce — bullish, momentum, short horizon
4 bullish / 1 bearish / 2 neutral, conflicted
Only PRCT
- Death Cross Active — bearish, trend, long horizon (17.37%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- Accumulation Pattern — bullish, volume, medium horizon (1.27x)
- Keltner Channel Breakout — bullish, volatility, short horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.
PRCT leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +5.89%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1PACB closes the Risk Resilience gap — currently 21 points behind, the largest single contributor to PRCT's edge.
- 2PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3PRCT's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | PACB | PRCT |
|---|---|---|
| Revenue growth (YoY) | 4% | 4% |
| EPS growth (YoY) | 14.3% | 2.1% |
| Gross margin | 34.5% | 64.7% |
| Operating margin | -99.6% | -33.6% |
| Return on equity (TTM) | 61.7% | -8.1% |
| Debt to equity | -11.49 | 0.23 |
Performance
PACB leads 4 of 6 windows| Metric | PACB | PRCT |
|---|---|---|
| 1 week (5 sessions) | -13.1% | 15.4% |
| 1 month (20 sessions) | 13.3% | 35.5% |
| 3 months (63 sessions) | 62% | 12.8% |
| 6 months (126 sessions) | 75% | -8.9% |
| Year to date | 4.8% | -24.3% |
| 1 year (252 sessions) | 12.6% | -22.7% |
Technicals
PRCT has the stronger structure| Metric | PACB | PRCT |
|---|---|---|
| RSI (14) | 43.1 | 69 |
| ADX (14) | 27.4 | 36.7 |
| Price vs 50-day | -8.7% | 29% |
| Price vs 200-day | 22.4% | 3.9% |
| Volatility (1M, annualized) | 114.1% | 64% |
Risk
PRCT is the more resilient| Metric | PACB | PRCT |
|---|---|---|
| Beta | 2.1 | 1.01 |
| Sharpe ratio | 0.61 | -0.11 |
| Sortino ratio | 0.96 | -0.15 |
| Max drawdown | -58.4% | -53.8% |
| Current drawdown | -32.4% | -34.1% |
| Annualized volatility | 93.5% | 65.9% |
| Value at risk (95%) | -9% | -6% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, PACB or PRCT?
On the Algovestiq AIQ Score, PRCT is the stronger of the two as of Nov 18, 2026, scoring 49 against PACB's 48. The edge comes from risk resilience and value. PACB is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is PACB or PRCT the better buy right now?
PRCT carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor PRCT over PACB?
The composite weights Quality, Value, Momentum and Risk Resilience. PACB leads Momentum by 24 points; PRCT leads Risk Resilience by 21 points; PRCT leads Value by 15 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, PACB or PRCT?
Analyst price targets imply +5.2% upside for PACB and +19.1% for PRCT, so the Street currently favors PRCT. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, PACB or PRCT?
PRCT is the better-valued of the two on the peer-relative Value factor. PRCT on the peer-relative Value factor, by 15 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, PACB or PRCT?
PACB on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, PACB or PRCT?
PACB on the Momentum factor, by 24 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, PACB or PRCT?
PRCT is the more resilient of the two, so the other name carries the higher downside risk. PRCT on Risk Resilience, by 21 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is PACB more profitable than PRCT?
The profitability evidence is mixed: gross margin 34.5% vs 64.7%; operating margin -99.6% vs -33.6%; ttm roe 61.7% vs -8.1%. PACB leads on one measure and PRCT on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is PRCT's lead over PACB getting stronger or weaker?
PRCT lead: Stable — the AIQ differential has held near 1 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has changed hands 4 times in that window, most recently on 2026-10-28, when PACB moved ahead of PRCT.
What would change the PACB vs PRCT verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PACB closes the Risk Resilience gap — currently 21 points behind, the largest single contributor to PRCT's edge; PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; PRCT's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about PACB and PRCT?
PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. PRCT: 4 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PACB is Golden Cross Active (bullish, long horizon). On PRCT it is Death Cross Active (bearish, long horizon).
Compare PACB and PRCT with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.